GDT 002
Alternative Names: GDT-002; TEG-002Latest Information Update: 25 Apr 2024
At a glance
- Originator Gadeta
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Ovarian cancer
- No development reported Multiple myeloma